Short-course intranasal LAT9997 therapy limits post-influenza bacterial pneumonia by recalibrating lung immunity
Authors:
Open Access
- 23 January 2026
- journal article
- Published by Elsevier in Mucosal Immunology
- Vol. 19 (2) , 1875-1888
Abstract
No abstract availableKeywords
Funding Information
- State Government of Victoria
This publication has 31 references indexed in Scilit:
- Community-Acquired PneumoniaJAMA, 2024
- The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysisEuropean Journal of Pharmacology, 2024
- Journey of monocytes and macrophages upon influenza A virus infectionCurrent Opinion in Virology, 2024
- Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infectionClinical & Translational Immunology, 2023
- Global morbidity and mortality of lower respiratory infections: A population -based studyRespiratory Medicine, 2022
- LanCLs add glutathione to dehydroamino acids generated at phosphorylated sites in the proteomeCell, 2021
- CD11b immunophenotyping identifies inflammatory profiles in the mouse and human lungsMucosal Immunology, 2016
- The role of influenza in the severity and transmission of respiratory bacterial diseaseThe Lancet Respiratory Medicine, 2014
- Inhibition of Akt kinase activity suppresses entry and replication of influenza virusBiochemical and Biophysical Research Communications, 2014
- Akt Determines Replicative Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells to Oxidative ApoptosisCancer Cell, 2008